Research programme: ADAPTIR mono-specific therapeutics - Aptevo Therapeutics

Drug Profile

Research programme: ADAPTIR mono-specific therapeutics - Aptevo Therapeutics

Alternative Names: A2M1; ADAPTIR™ mono-specific therapeutics; AH65; anti-CD20 SMIP; DRACO; DRACO anti-CD3 SMIP; ES 301; SMIP - Emergent BioSolutions; SMIPs - Emergent/Pfizer; X1 - Emergent BioSolutions

Latest Information Update: 02 Sep 2016

Price : $50

At a glance

  • Originator Trubion Pharmaceuticals
  • Developer Aptevo Therapeutics
  • Class Antibodies; Peptides; Protein diagnostics
  • Mechanism of Action CD20 antigen modulators; CD3 antigen inhibitors; Immunosuppressants; T-cell receptor antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer

Most Recent Events

  • 01 Aug 2016 Emergent BioSolutions forms a spin-off Aptevo Therapeutics for its oncology and haematology products
  • 19 Apr 2013 Candidates from this research programme are available for licensing as of 19 Apr 2013. http://www.emergentbiosolutions.com/
  • 01 Apr 2013 Preclinical trials in Autoimmune disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top